GlassScriptPhysician profile
Evans P Tran
NPI 1750632253
$13,804.65
in general payments reported to CMS, 2019-2025
34 companies · $846 in 2025
The $846 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,922 · 2022: $6,248 · 2023: $3,185 · 2024: $604 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504 · Travel and Lodging: $1,031 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.58 |
| Travel and Lodging | $1,031.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $7,228.01 | 2021-2025 | Urolift |
| Axonics, INC. | $1,662.80 | 2021-2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $713.61 | 2021-2025 | Provenge |
| Medtronic, INC. | $684.94 | 2021-2023 | Interstim |
| Astellas Pharma US INC | $554.51 | 2021-2023 | |
| Antares Pharma, INC. | $493.42 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Progenics Pharmaceuticals, INC. | $323.06 | 2021-2025 | Pylarify |
| Accord Healthcare, INC. | $294.32 | 2023-2025 | |
| Abbvie INC. | $223.97 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $215.02 | 2023-2025 | Orgovyx, Gemtesa |
| Halozyme INC | $204.24 | 2023 | |
| Pfizer INC. | $203.62 | 2022-2024 | |
| Myovant Sciences INC. | $178.80 | 2021-2022 | |
| Janssen Biotech, INC. | $161.33 | 2021-2025 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $82.09 | 2023-2025 | Keytruda, Lynparza, Welireg |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $57.43 | 2024 | |
| Novartis Pharmaceuticals Corporation | $53.54 | 2025 | |
| Acerus Pharmaceuticals Corporation | $46.46 | 2021 | |
| Olympus America INC. | $45.69 | 2021-2025 | Itind System |
| Tolmar Pharmaceuticals, INC. | $43.76 | 2021 | |
| Endo Pharmaceuticals INC. | $39.78 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $38.40 | 2021-2023 | Prolaris |
| Fujifilm Healthcare Americas Corporation | $29.91 | 2023 | Arietta Precision |
| Bayer Healthcare Pharmaceuticals INC. | $26.63 | 2023 | |
| Procept Biorobotics Corporation | $26.53 | 2023 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $26.18 | 2022 | |
| Verity Pharmaceuticals INC. | $24.05 | 2023 | Trelstar |
| Boston Scientific Corporation | $21.28 | 2021 | |
| Sagent Pharmaceuticals | $19.82 | 2025 | Glydo |
| Stryker Corporation | $18.38 | 2024 | 1788 |
| Alnylam Pharmaceuticals INC. | $17.89 | 2022 | |
| Ethicon US, LLC | $15.61 | 2025 | Stratafix |
| Photocure INC | $15.01 | 2024 | Cysview |
| Agiliti Surgical, INC. | $14.56 | 2023 | Sonablate, Trinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evans Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.